Filing Details

Accession Number:
0001415889-24-001545
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-18 18:28:44
Reporting Period:
2024-01-16
Accepted Time:
2024-01-18 18:28:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
855654 Immunogen Inc. IMGN Pharmaceutical Preparations (2834) 042726691
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1510720 Theresa Wingrove C/O Immunogen, Inc.
830 Winter Street
Waltham MA 02451
Svp Of Regulatory Affairs No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-16 58,900 $4.83 62,326 No 4 M Direct
Common Stock Acquisiton 2024-01-16 2,667 $5.75 64,993 No 4 M Direct
Common Stock Acquisiton 2024-01-16 126,100 $5.25 191,093 No 4 M Direct
Common Stock Disposition 2024-01-16 187,667 $29.64 3,426 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2024-01-16 58,900 $0.00 58,900 $4.83
Common Stock Stock Option (right to buy) Disposition 2024-01-16 2,667 $0.00 2,667 $5.75
Common Stock Stock Option (Right to Buy) Disposition 2024-01-16 126,100 $0.00 126,100 $5.25
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2029-02-05 No 4 M Direct
1,333 2026-06-01 No 4 M Direct
0 2029-01-31 No 4 M Direct
Footnotes
  1. Effected pursuant to a trading plan adopted on June 13, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.60 to $29.71, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
  3. This option was granted on 2/5/2019 and is fully vested as of the date of this transaction.
  4. This option was granted on 6/01/2016 and is fully vested as of the date of this transaction.
  5. This option was granted on 01/31/2019 and is fully vested as of the date of this transaction.